文献速递淋巴瘤造血干细胞移植与细胞治疗

血清神经丝轻链水平与CAR-T细胞治疗后神经毒性严重程度相关

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment.
PubMed 文献 · Blood Adv · 2022-01-01

该研究在2个主要CAR-T治疗中心纳入96例接受CD19靶向CAR-T细胞治疗的难治性B细胞恶性肿瘤患者,用单分子酶联免疫吸附法测定输注前后血清神经丝轻链(NfL)水平,发现治疗前NfL升高与更严重的免疫效应细胞相关神经毒性综合征(ICANS)相关,输注后NfL显著升高且与ICANS严重程度相关。

要点

  • 治疗前血清NfL升高与CAR-T治疗后更严重的ICANS相关。
  • CAR-T输注后NfL水平显著升高,且与ICANS严重程度相关。
  • 血清NfL可能作为预测ICANS严重程度的生物标志物。

核心结论

  • 治疗前血清NfL水平升高与CAR-T治疗后更严重的ICANS相关,输注后NfL显著升高亦与ICANS严重程度相关。
  • 血清NfL水平可能作为预测ICANS严重程度和改善CAR-T输注后患者监测的生物标志物。
  • 这些初步结果需在更大的前瞻性队列中验证。

研究设计与样本

  • 研究纳入96例接受CAR-T细胞治疗难治性B细胞恶性肿瘤的患者,来自2个主要CAR-T细胞治疗中心。
  • 采用单分子酶联免疫吸附法测定CAR-T细胞输注前后的血清NfL水平,并与ICANS严重程度进行相关性分析。

主要发现

  • 治疗前血清NfL水平升高与更严重的ICANS相关,该关联在未调整和调整分析中均存在。
  • 多变量统计模型显示CAR-T细胞输注后NfL水平显著升高,且与ICANS严重程度相关。
  • 以治疗前NfL水平较高为特征的既存神经轴索损伤与后续ICANS严重程度相关。

临床怎么用

  • 作者认为血清NfL水平可能作为预测ICANS严重程度和改善CAR-T输注后患者监测的生物标志物。

局限性

  • 作者指出这些初步结果需在更大的前瞻性患者队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antitumor therapy with CD19-targeted chimeric antigen receptor (CAR) modified T cells is highly efficient. However, treatment is often complicated by a unique profile of unpredictable neurotoxic adverse effects of varying degrees known as immune effector cell-associated neurotoxicity syndrome (ICANS). We examined 96 patients receiving CAR T cells for refractory B-cell malignancies at 2 major CAR T-cell treatment centers to determine whether serum levels of neurofilament light chain (NfL), a marker of neuroaxonal injury, correlate with the severity of ICANS. Serum NfL levels were measured before and after infusion of CAR T cells using a single-molecule enzyme-linked immunosorbent assay and correlated with the severity of ICANS. Elevated NfL serum levels before treatment were associated with more severe ICANS in both unadjusted and adjusted analyses. Multivariable statistical models revealed a significant increase in NfL levels after CAR T-cell infusion, which correlated with the severity of ICANS. Preexisting neuroaxonal injury. which was characterized by higher NfL levels before CAR T-cell treatment, correlated with the severity of subsequent ICANS. Thus, serum NfL level might serve as a predictive biomarker for assessing the severity of ICANS and for improving patient monitoring after CAR T-cell transfusion. However, these preliminary results should be validated in a larger prospective cohort of patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schoeberl F, Tiedt S, Schmitt A, et al. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Adv. 2022. PMID: 35042236. doi:10.1182/bloodadvances.2021006144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。